Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...